Anthony Mancini

Rasonque's approval closed its compassionate-use program before insurers were ready to pay

Revolution Medicines' expanded access program for Rasonque closed immediately on FDA approval, leaving patients still mid-application to wait on insurers whose paperwork moves slower than metastatic pancreatic cancer.